basiliximab
Sign in to saveAlso known as CHI621, SDZ-CHI-621, CHI-621, chimeric mouse-human antiCD25, Ig gamma-1 chain C region
compuesto químico
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 459525440
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- xi/o
- Drug.target
- CD25
- Drug.tradename
- Simulect
- Drug.MedlinePlus
- a612013
- Drug.licence_EU
- yes
- Drug.DailyMedID
- Basiliximab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous
- Drug.class
- Immunosuppressants
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AC02
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 1998
- Admin. routes
- parenteral
- Indications
- neoplasm, ulcerative colitis, immune system disease, chronic kidney disease
via ChEMBL · EBI
Research
1,835 papers- Basiliximab.Drugs · 1999
- Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials.Hepatobiliary & pancreatic diseases international : HBPD INT · 2017
- Basiliximab: a review of its use as induction therapy in renal transplantation.Drugs · 2003
- Treatment Options in Refractory Autoimmune Encephalitis.CNS drugs · 2022
- Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis.Transplantation proceedings · 2010
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 6 more facts
- defined daily dose
- 40
- World Health Organisation international non-proprietary name
- basiliximab
- subject has role
- monoclonal antibody
- chemical formula
- C₆₃₇₈H₉₈₄₄N₁₆₉₈O₁₉₉₇S₄₈
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
Sources (7)
via Wikidata · CC0
Article · Español
Basiliximab (Simulect) es un anticuerpo monoclonal que actúa como inmunosupresor. Se obtiene por ingeniería genética con murinos y células humanas.Es un compuesto quimérico fabricado por tecnología de ADN recombinante, tiene con una molécula de inmunoglobulina G (IgG); como glicoproteína se forma de un 75% humano y 25% murino. Es un producto de Novartis Pharmaceuticals y fue aprobado por la FDA en 1998.Es análogo al .
Abstract from DBpedia / Wikipedia · CC BY-SA